Table 1.
The clinicopathological characteristics and treatment strategies of the enrolled patients.
| Clinical characteristics | Overall | |
|---|---|---|
| (n = 33) | ||
| Age | ||
| Median [Range] | 58.4 [29.3–73.5] | |
| Gender (%) | ||
| Female | 8 (24.2%) | |
| Male | 25 (75.8%) | |
| Smoking history (%) | ||
| No | 14 (42.4%) | |
| Yes | 19 (57.6%) | |
| Pathology (%) | ||
| Adenocarcinoma | 32 (97.0%) | |
| Pulmonary sarcomatoid carcinoma | 1 (3.0%) | |
| Stage (%) | ||
| III | 1 (3.0%) | |
| IV | 32 (97.0%) | |
| Performance status score (%) | ||
| 1 | 32 (97.0%) | |
| 2 | 1 (3.0%) | |
| Brain metastasis (%) | ||
| No | 23 (69.7%) | |
| Yes | 10 (30.3%) | |
| EGFR mutation (%) | ||
| 19DEL | 5 (15.2%) | |
| L858R | 8 (24.2%) | |
| Negative | 20 (60.6%) | |
| MET FISH (%) | ||
| Negative | 7 (21.2%) | |
| Positive | 16 (48.5%) | |
| NA | 10 (30.3%) | |
| MET IHC (%) | ||
| Negative | 11 (33.3%) | |
| Positive | 22 (66.7%) | |
| Treatment (%) | ||
| MET inhibitor + EGFR-TKI | 12 (36.4%) | |
| MET inhibitor | 21 (63.6%) | |
| Treatment line (%) | ||
| 1 | 7 (21.2%) | |
| ≥2 | 26 (78.2%) | |